Trial Profile
A Phase II Study of Bortezomib (VELCADE) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 03 Aug 2012 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 18 Feb 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 18 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.